SUMMARY
This paper reports on selected oral abstracts presented at ASH 2021 on the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients.
(BELG J HEMATOL 2022;13(1):5–10)
This paper reports on selected oral abstracts presented at ASH 2021 on the treatment of newly diagnosed and relapsed/refractory multiple myeloma (MM) patients.
(BELG J HEMATOL 2022;13(1):5–10)
* (only possible for healthcare professionals with RIZIV/INAMI/MATRICULE working in the field of Hematology in Belgium and Luxembourg with prescription authorisation)
** (for healthcare professionals with prescribing authorisation working outside the field of Hematology in Belgium and Luxembourg as well as those without prescribing authorisation working as healthcare professional in Hematology in Belgium and Luxembourg, plus persons without prescription authorisation working outside Belgium and Luxembourg, plus healthcare professionals with prescribing authorisation outside Belgium and Luxembourg plus non-healthcare professionals from outside or inside Belgium or Luxembourg)
Top
